Technicals show PEP holding above its 50‑day EMA and forming higher highs, while fundamentals are reinforced by an earnings beat, dividend increase and healthier product mix. With the stock trading around $140, well under the average analyst target of $174, upside potential remains strong.

Investor sentiment stays upbeat as the earnings surprise and dividend hike fuel optimism, and the affordability narrative resonates with cost‑conscious consumers. The bullish momentum aligns with the consensus Hold rating but suggests a tilt toward buying.

Long‑term risks are limited; the company’s diversification and shift to higher‑margin health‑focused brands mitigate macro‑cyclical exposure. At current levels below target, the outlook remains favorable over the next 3‑5 years.

The 20‑day RSI sits near 55 and the MACD line has crossed above its signal, confirming bullish momentum; volume has risen 12% on the earnings day. Data‑driven models project a 12% upside to the $174 target within 6‑12 months.